AFRICAN-AMERICAN STUDY OF KIDNEY DISEASE AND HYPERTENSION (AASK)

非裔美国人肾脏疾病和高血压研究 (AASK)

• 批准号: 7604531
• 负责人: Brad C Astor
• 金额: $ 0.42万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7604531
• 关键词: Address; Adverse event; African American; Amlodipine; Antihypertensive Agents; Blood Pressure; Blood specimen; Cardiovascular system; Caring; Cessation of life; Clinical; Clinical Trials; Cohort Studies; Collection; Computer Retrieval of Information on Scientific Projects Database; Creatinine; DNA; Data; Disease Progression; Echocardiography; Economic Factors; Electrocardiogram; End stage renal failure; Enrollment; Fasting; Funding; Genetic; Grant; Heavy Metals; Hour; Hypertension; Institution; Kidney; Kidney Diseases; Lead; Measurement; Medical Surveillance; Metoprolol; Monitor; Outcome; Participant; Pharmaceutical Preparations; Physiologic pulse; Physiological; Prevention strategy; Procedures; Process; Pulse taking; Questionnaires; Ramipril; Randomized Clinical Trials; Research; Research Personnel; Resources; Serum; Source; Structure of nail of finger; Testing; Tissues; United States National Institutes of Health; Urine; Visit; blood pressure regulation; cohort; follow-up; two-dimensional

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The AASK trial was a randomized, clinical trial that tested the effects on kidney disease of 3 different medications used as first line antihypertensive therapy (ramipril, metoprolol and amlodipine) and 2 levels of blood pressure control (usual control and more aggressive control). The AASK Cohort Study enrolled subjects who had participated in the AASK clinical trial. Exposures include environmental, genetic, physiologic, and socio-economic factors. The primary renal outcome is a clinical outcome defined by doubling of serum creatinine, end-stage renal disease (ESRD) or death. Data related to ascertainment of exposures and surveillance of outcomes are collected at baseline and every 12 months thereafter. Management of antihypertensive therapy occurs at these visits and at an additional 2 to 4 visits/year. Core measurements include the following: blood pressure, fasting blood specimens, DNA, 24-hour urine collection, finger nails (for heavy metals), questionnaires and cardiovascular procedures (ECG; 2 dimensional, M-mode, pulsed Doppler and pulsed tissue Doppler echocardiogram; and 24-hour ambulatory BP recordings). Appropriate antihypertensive treatment (medications and target BP level as determined in the AASK trial) is provided to all participants who do not have ESRD. In this fashion, the cohort directly controls two of the major `known' determinants of kidney disease progression (control of hypertension and use of reno-protective, antihypertensive medication) and therefore addresses research questions in the setting of recommended antihypertensive care. The anticipated duration of follow-up in the Cohort Study is 5 years (total of 9-12 years, including the period of the AASK trial). An independent DSMB monitors all aspects of the study, and reviews all adverse events. Ultimately, data from the AASK cohort study should enhance our understanding of the processes that determine progression of renal disease. Successful completion of this study might also lead to new prevention strategies that delay the onset of ESRD.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 AASK 试验是一项随机临床试验，测试了用作一线抗高血压治疗的 3 种不同药物（雷米普利、美托洛尔和氨氯地平）和 2 种血压控制水平（普通控制和更积极的控制）对肾脏疾病的影响。 AASK 队列研究招募了参加过 AASK 临床试验的受试者。 暴露包括环境、遗传、生理和社会经济因素。 主要肾脏结局是指血清肌酐加倍、终末期肾病 (ESRD) 或死亡定义的临床结局。 与暴露确定和结果监测相关的数据在基线时以及此后每 12 个月收集一次。 在这些就诊以及每年另外 2 至 4 次就诊时进行抗高血压治疗。 核心测量包括以下内容：血压、空腹血液样本、DNA、24小时尿液采集、指甲（重金属）、问卷调查和心血管检查（心电图；二维、M型、脉冲多普勒和脉冲组织多普勒超声心动图；以及24小时动态血压记录）。 向所有没有 ESRD 的参与者提供适当的抗高血压治疗（AASK 试验中确定的药物和目标血压水平）。 通过这种方式，该队列直接控制肾脏疾病进展的两个主要“已知”决定因素（控制高血压和使用保护肾脏的抗高血压药物），因此解决了推荐抗高血压治疗中的研究问题。 队列研究的预期随访时间为 5 年（总计 9-12 年，包括 AASK 试验期间）。 独立的 DSMB 监控研究的各个方面，并审查所有不良事件。 最终，AASK 队列研究的数据应该会增强我们对决定肾脏疾病进展过程的理解。 这项研究的成功完成也可能会带来延迟 ESRD 发病的新预防策略。